npj Precision Oncology, Год журнала: 2025, Номер 9(1)

Опубликована: Март 24, 2025

Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, evidenced by its increasing integration into clinical practice. Carrying specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide comprehensive, up-to-date summary of monitoring response with focus on lung, colorectal, breast cancers, discuss current challenges future directions.

Язык: Английский